Diagnosis and Treatment of Patients With Focal Segmental Glomerulosclerosis/Steroid-Resistant Nephrotic Syndrome: A Delphi Survey
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F22%3A10448753" target="_blank" >RIV/00064165:_____/22:10448753 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/22:10448753
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Naz1VBlggm" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Naz1VBlggm</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ekir.2022.06.010" target="_blank" >10.1016/j.ekir.2022.06.010</a>
Alternative languages
Result language
angličtina
Original language name
Diagnosis and Treatment of Patients With Focal Segmental Glomerulosclerosis/Steroid-Resistant Nephrotic Syndrome: A Delphi Survey
Original language description
Focal segmental glomerulosclerosis (FSGS) is a histopathologic pattern of podocyte injury with several underlying etiologies and is characterized by segmental scarring that involves part of the glomerulus and a subset of glomeruli sampled on biopsy. In adults, nephrotic syndrome (NS) is often characteristic of primary (or idiopathic) FSGS. In children, steroid-resistantnephrotic syndrome (SRNS) is an indication for kidney biopsy and most commonly associated with FSGS histologically. Available treatments do not always produce complete remission, and patients who do not achieve remission often progress to chronic kidney failure. FSGS classification (primary, secondary, genetic, or undetermined cause) and patient-specific factors are used to individualize patient treatment in terms of medications used, dosing, and length of treatment. International guidelines are available to help nephrologists develop management strategies for patients with FSGS or SRNS, but the extent to which nephrologists agree with and may apply this guidance is unknown. The Delphi FSGS and IgA Nephropathy Experts (DEFINE): Physicians study aimed to find consensus on pathophysiology, diagnosis, monitoring, and management of FSGS and IgA nephropathy among nephrologists from Canada, France, Germany, Italy, Spain, the United Kingdom, and the United States. In this 2-round online Delphi survey, agreement with 22 statements about FSGS/SRNS was scored by adult and pediatric nephrologists using a 1 to 9 Likert scale (9 = strongly agree). Moderate versus high consensus were defined as 75% to 89% versus >=90% of participants scoring 7 to 9 on the Likert scale, respectively. Between November 2020 and April 2021, 207 nephrologists completed round 1, and 158 (76%) nephrologists completed round 2 (Figure S1, Tables S1-S4). Methods and participant characteristics are detailed in the Supplementary Materials.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30217 - Urology and nephrology
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Kidney International Reports
ISSN
2468-0249
e-ISSN
2468-0249
Volume of the periodical
7
Issue of the periodical within the volume
9
Country of publishing house
US - UNITED STATES
Number of pages
5
Pages from-to
2081-2085
UT code for WoS article
000863107700017
EID of the result in the Scopus database
2-s2.0-85134342309